Evidence map›Paper›PMID 39495512›Full record

ArticleJAMA network open2024

Hospital COVID-19 Burden and Adverse Event Rates.

Mark L Metersky, David Rodrick, Shih-Yieh Ho, Deron Galusha, Andrea Timashenka, Erin N Grace, Darryl Marshall, Sheila Eckenrode, Harlan M Krumholz

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Impact of the COVID-19 Pandemic on Inpatient Cancer Treatment and Outcomes in the United States.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026
    Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark L MeterskyDivision of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut School of Medicine, Farmington.
David RodrickAgency for Healthcare Research and Quality, Department of Health and Human Services, Washington, DC.
Shih-Yieh HoCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.
Deron GalushaCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.
Andrea TimashenkaAgency for Healthcare Research and Quality, Department of Health and Human Services, Washington, DC.
Erin N GraceAgency for Healthcare Research and Quality, Department of Health and Human Services, Washington, DC.
Darryl MarshallAgency for Healthcare Research and Quality, Department of Health and Human Services, Washington, DC.
Sheila EckenrodeCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.
Harlan M KrumholzCenter for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Importance: The COVID-19 pandemic introduced stresses on hospitals due to the surge in demand for care and to staffing shortages. The implications of these stresses for patient safety are not well understood. Objective: To assess whether hospital COVID-19 burden was associated with the rate of in-hospital adverse effects (AEs). Design, Setting, and Participants: This cohort study used data from the Agency for Healthcare Research and Quality's Quality and Safety Review System, a surveillance system that tracks the frequency of AEs among selected hospital admissions across the US. The study sample included randomly selected Medicare patient admissions to acute care hospitals in the US between September 1, 2020, and June 30, 2022. Main Outcomes and Measures: The main outcome was the association between frequency of AEs and hospital-specific weekly COVID-19 burden. Observed and risk-adjusted rates of AEs per 1000 admissions were stratified by the weekly hospital-specific COVID-19 burden (daily mean number of COVID-19 inpatients per 100 hospital beds each week), presented as less than the 25th percentile (lowest burden), 25th to 75th percentile (intermediate burden), and greater than the 75th percentile (highest burden). Risk adjustment variables included patient and hospital characteristics. Results: The study included 40 737 Medicare hospital admissions (4114 patients [10.1%] with COVID-19 and 36 623 [89.9%] without); mean (SD) patient age was 73.8 (12.1) years, 53.8% were female, and the median number of Elixhauser comorbidities was 4 (IQR, 2-5). There were 59.1 (95% CI, 54.5-64.0) AEs per 1000 admissions during weeks with the lowest, 77.0 (95% CI, 73.3-80.9) AEs per 1000 admissions during weeks with intermediate, and 97.4 (95% CI, 91.6-103.7) AEs per 1000 admissions during weeks with the highest COVID-19 burden. Among patients without COVID-19, there were 55.7 (95% CI, 51.1-60.8) AEs per 1000 admissions during weeks with the lowest, 74.0 (95% CI, 70.2-78.1) AEs per 1000 admissions during weeks with intermediate, and 79.3 (95% CI, 73.7-85.3) AEs per 1000 admissions during weeks with the highest COVID-19 burden. A similar pattern was seen among patients with COVID-19. After risk adjustment, the relative risk (RR) for AEs among patients admitted during weeks with high compared with low COVID-19 burden for all patients was 1.23 (95% CI, 1.09-1.39; P < .001), with similar results seen in the cohorts with (RR, 1.33; 95% CI, 1.03-1.71; P = .03) and without (RR, 1.23; 95% CI, 1.08-1.39; P = .002) COVID-19 individually. Conclusions and Relevance: In this cohort study of hospital admissions among Medicare patients during the COVID-19 pandemic, greater hospital COVID-19 burden was associated with an increased risk of in-hospital AEs among both patients with and without COVID-19. These results illustrate the need for greater hospital resilience and surge capacity to prevent declines in patient safety during surges in demand.

Indexed as

Cost of IllnessCOVID-19HospitalsPatient SafetyAgedFemaleHospitalizationHumansMaleUnited States

Identifiers

PMID39495512
PMCPMC11581512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.